Orelabrutinib (ICP-022)
Orelabrutinib is a potent and irreversible Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Orelabrutinib prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK.
Product Specifications
Shipping Conditions
Gel Pack
Storage Conditions
-20ºC
Shelf Life
36 months
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog